Veracyte Inc VCYT Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Apr 01, 2024 (filed on Apr 02, 2024)

Insider Name:

Eastham Karin

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-10,000

Price:

$13.19
Apr 01, 2024 (filed on Apr 02, 2024)

Insider Name:

Eastham Karin

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-10,000

Price:

$21.65
Apr 01, 2024 (filed on Apr 02, 2024)

Insider Name:

Eastham Karin

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

10,000

Price:

$13.19
Mar 15, 2024 (filed on Mar 19, 2024)

Insider Name:

Chambers Rebecca

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-2,189

Price:

$21.10
Mar 15, 2024 (filed on Mar 19, 2024)

Insider Name:

Chambers Rebecca

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

4,318

Price:

--
Mar 15, 2024 (filed on Mar 19, 2024)

Insider Name:

Stapley Marc

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-5,971

Price:

$21.10
Mar 15, 2024 (filed on Mar 19, 2024)

Insider Name:

Stapley Marc

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

11,780

Price:

--
Mar 06, 2024 (filed on Mar 08, 2024)

Insider Name:

Stapley Marc

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

114,724

Price:

--
Mar 06, 2024 (filed on Mar 08, 2024)

Insider Name:

Leite John

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

49,880

Price:

--
Mar 06, 2024 (filed on Mar 08, 2024)

Insider Name:

McGuire Annie

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

49,880

Price:

--

Filings by filing date

Apr 01, 2024 (filed on Apr 02, 2024)

Insider Name:

Eastham Karin

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-10,000

Price:

$13.19
Apr 01, 2024 (filed on Apr 02, 2024)

Insider Name:

Eastham Karin

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-10,000

Price:

$21.65
Apr 01, 2024 (filed on Apr 02, 2024)

Insider Name:

Eastham Karin

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

10,000

Price:

$13.19
Mar 15, 2024 (filed on Mar 19, 2024)

Insider Name:

Chambers Rebecca

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-2,189

Price:

$21.10
Mar 15, 2024 (filed on Mar 19, 2024)

Insider Name:

Chambers Rebecca

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

4,318

Price:

--
Mar 15, 2024 (filed on Mar 19, 2024)

Insider Name:

Stapley Marc

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-5,971

Price:

$21.10
Mar 15, 2024 (filed on Mar 19, 2024)

Insider Name:

Stapley Marc

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

11,780

Price:

--
Mar 06, 2024 (filed on Mar 08, 2024)

Insider Name:

Stapley Marc

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

114,724

Price:

--
Mar 06, 2024 (filed on Mar 08, 2024)

Insider Name:

Leite John

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

49,880

Price:

--
Mar 06, 2024 (filed on Mar 08, 2024)

Insider Name:

McGuire Annie

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

49,880

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	6000 Shoreline Court, Suite 300 SOUTH SAN FRANCISCO CA 94080
Tel:	N/A
Website:	https://www.veracyte.com
IR:	See website

Key People

Marc A. Stapley Chief Executive Officer, Director	Rebecca Chambers Chief Financial Officer	Annie Mcguire Chief People Officer, Executive Vice President
Phillip G. Febbo Chief Scientific Officer, Chief Medical Officer

Business Overview

Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.

Financial Overview

For the fiscal year ended 31 December 2023, Veracyte Inc revenues increased 22% to $361.1M. Net loss increased from $36.6M to $74.4M. Revenues reflect United States segment increase of 27% to $334.5M. Higher net loss reflects Research and development - Balancing increase of 50% to $51.1M (expense), General & Administrative Expenses increase of 16% to $66.2M (expense).

Employees:	815 as of Dec 31, 2023

Reporting Currency:	U.S. Dollars
Enterprise value:	$1,339M as of Dec 31, 2023
Annual revenue (TTM):	$361.05M as of Dec 31, 2023
EBITDA (TTM):	$9.73M as of Dec 31, 2023
Net annual income (TTM):	-$74.40M as of Dec 31, 2023
Free cash flow (TTM):	$34.26M as of Dec 31, 2023
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	78,436,369 as of Mar 22, 2024
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization